Patients with prostate cancer can be saved from receiving chemotherapy after new studies have found ways to “cure smarter, less difficult”.
Scientists at University College London (UCL) have found that chemotherapy is significantly more effective for some advanced men. Prostate cancer Than others.
Treatment is usually given to all men diagnosed with advanced prostate cancer in parallel with hormone therapy.
About 47,500 men Diagnosed with cancer every year 6,000 are highly classified.
However, a new study presented at the American Society of Clinical Oncology’s annual meeting in Chicago this month found that some men with advanced-stage prostate cancer did not benefit from chemotherapy at all. understood.
Those who had multiple metastases (secondary tumors) at the time of diagnosis, and those who had larger tumors, experienced greater benefits from chemotherapy than those who had hormone therapy alone.
Five years later, 38% of men with multiple metastases who received docetaxel, the most common form of chemotherapy for prostate cancer, survived, compared with 26% of men who received hormone therapy alone. was.
Among those who had larger tumors, 58 percent survived for 5 years-39 percent increase, compared to 19 percent with hormone therapy alone.
However, men with few metastases who were previously diagnosed with tumors did not benefit from chemotherapy at all.
During the pandemic, due to the potential effects of chemotherapy on the immune system, docetaxel was prescribed less frequently in favor of newer hormonal therapies.
Data from the National Prostate Cancer Audit show that between April and December 2020, the number of men with hormone-sensitive metastatic cancer receiving docetaxel decreased by 74%.
This study helps doctors direct chemotherapy to the most effective people, but others may be offered alternative life-prolonging treatments that can avoid negative side effects.
Patients receiving chemotherapy often experience nausea, hair loss, malaise, loss of appetite, and infections.
Dr. Claire Vale, Research Author and Principal Investigator, Clinical Trials Unit, University College London, said: In this case, the evidence is clear and we want to be incorporated into clinical practice as soon as possible. “
Dr. Hayley Luxton, Research Impact Manager at Prostate Cancer UK, said: “”